Definition of BE (EMA) [Design Issues]

posted by BarbaraM – Greece, 2014-08-07 18:31 (4342 d 21:22 ago) – Posting: # 13350
Views: 9,699

Hi! thank you both for the quick feedback and the Greek salut :-).

Indeed I'm referring to a standard 2-way cross over BE. My concern rises from the fact that if we dose 1 tab of 1000 mg (highest strength) then depending on the subject's body weight this will result in doses much less than the 25 mg/kg that is specified in the SmPC (e.g. for the 60 kg subject would result in ~17 mg/kg) and I assume that this will result in a Cmax and AUC less than the SmPC proposes.
It would be as if we had 2 strength of a product and we were to dose the smallest strength, instead of the highest as the EMA guideline proposes to be the most discriminatory case.

What do you think? Does this make any sense?

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
188 visitors (0 registered, 188 guests [including 11 identified bots]).
Forum time: 15:53 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5